BioRestorative Announces Closing of $5.0 Million Public Offering
Globe Newswire (Fri, 13-Feb 8:30 PM ET)
Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Benzinga (Thu, 12-Feb 4:31 AM ET)
BioRestorative prices $5M stock offering
Seeking Alpha News (Thu, 12-Feb 12:55 AM ET)
BioRestorative Announces Pricing of $5.0 Million Public Offering
Globe Newswire (Wed, 11-Feb 10:30 PM ET)
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
Globe Newswire (Wed, 11-Feb 7:30 AM ET)
Globe Newswire (Tue, 10-Feb 8:00 AM ET)
Benzinga (Tue, 10-Feb 4:45 AM ET)
Globe Newswire (Mon, 17-Nov 7:00 AM ET)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Biorestorative Therapies trades on the NASDAQ stock market under the symbol BRTX.
As of February 13, 2026, BRTX stock price climbed to $0.28 with 14,366,301 million shares trading.
BRTX has a beta of 1.16, meaning it tends to be more sensitive to market movements. BRTX has a correlation of 0.02 to the broad based SPY ETF.
BRTX has a market cap of $2.53 million. This is considered a Sub-Micro Cap stock.
Last quarter Biorestorative Therapies reported $11,800 in Revenue and -$.33 earnings per share. This fell short of revenue expectation by $-424,200 and exceeded earnings estimates by $.05.
In the last 3 years, BRTX traded as high as $7.13 and as low as $.22.
The top ETF exchange traded funds that BRTX belongs to (by Net Assets): VXF.
BRTX has underperformed the market in the last year with a price return of -88.4% while the SPY ETF gained +13.0%. BRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -77.2% and -75.0%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
BRTX support price is $.23 and resistance is $.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRTX shares will trade within this expected range on the day.
